Polyoma Virus Jc Peptides And Proteins In Vaccination And Diagnostic Applications

Full-text?

The full document isn't yet available to us from the patent office.

Abstract

The present invention relates to the field of vaccination or immunization, in particular therapeutic vaccination, and diagnosis. Pharmaceutical compositions and kits capable of eliciting a protective immune response against polyoma virus JC (JCV) are disclosed, which may be used e.g., for therapy or for prevention of progressive multifocal leukoencephalopathy (PML) and/or progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome (PML-IRIS). Individuals in danger of such PML or PML-IRIS may, e.g., be immunocompromised or immunosuppressed patients or patients having an autoimmune disease eligible for immunosuppressive treatment. The invention also relates to compositions comprising at least one CD4+ epitope of a JCV protein and to diagnostic uses thereof.


Claims

Information currently unavailable.

CPC Classifications
Download PDF
Document Preview
Document History
  • Publication: Jan 23, 2013
  • Application: Jul 22, 2011
    EP EP 11006031 A
  • Priority: Jul 22, 2011
    EP EP 11006031 A

Download Citation


Sign in to the Lens

Feedback